Citations

Showing 10 of 108104 citations.

Inflammatory Diabetic Neuropathy: Helpful Diagnostic Parameters
Thaisetthawatkul, Pariwat , Fernandes, J. Americo, Piccione, Ezequiel, Truong, Laetitia, Dyck, Peter James

Mayo Clinic

Journal of Clinical Neuromuscular Disease | August 20, 2018 | Volume: 20 | Issue: 1 | Pages: 7-13

10.1097/cnd.0000000000000207 | PMID 30124555 Get It

Abstract Objectives: Mild inflammatory diabetic neuropathies (IDNs) overlap with diabetic sensorimotor neuropathy (DPN) in clinical presentation and electrophysiological and laboratory tests. This study is to determine whether IDN can be differentiated from DPN by clinical features, electrophysiological, pathological, or laboratory tests. Methods: Suspected IDN cases were identified by a subacute onset and progressive sensory or motor neuropathy in patients with diabetes. Results: IDN occurred earlier in the course of diabetes mellitus and had higher prevalence of limb weakness, walking difficulty, and more severe electrophysiological abnormalities suggesting both demyelination and axonal loss. Sensory nerve biopsies in IDN showed perivascular inflammatory infiltrates, decreased fiber density, increased demyelination, and axonal degeneration. Most patients with IDN improved with immunotherapy. Conclusions: Features that favor IDN over DPN are limb weakness, more severe nerve conduction abnormalities, inflammatory infiltrates on nerve biopsy, and a favorable response to immunotherapy. A nerve biopsy can help establish an inflammatory cause.
Case of Early Amyotrophic Lateral Sclerosis With Prominent Magnetic Resonance Imaging Plexus Abnormalities
Zubair, Adeel , Amrami, Kimberly K. , Crum, Brian A. , Zubair, Adeel S. , Mustafa, Rafid , Crum, Brian A

Mayo Clinic

Journal of Clinical Neuromuscular Disease | August 20, 2018 | Volume: 20 | Issue: 1 | Pages: 41-44

10.1097/cnd.0000000000000206 | PMID 30124559 Get It

Abstract Amyotrophic lateral sclerosis is a neurodegenerative disorder, which is characterized by progressive upper and lower motor neuron signs and symptoms, resulting in progressive muscle weakness. There are very rare reports of magnetic resonance imaging (MRI) abnormalities within the nerve roots or plexus reported in amyotrophic lateral sclerosis. Here, we report a patient who presented with progressive left arm weakness and was found to have bilateral MRI plexus abnormalities. This report illustrates that MRI plexus abnormalities can be seen in amyotrophic lateral sclerosis, possibly before symptoms, and may have clinical value in the diagnostic process.
Current landscape and future perspective of sentinel node mapping in endometrial cancer
Bogani, Giorgio , Raspagliesi, Francesco , Maggiore, Umberto Leone Roberti , Raspagliesi, Francesco , Leone Roberti Maggiore, Umberto , Mariani, Andrea , Bogani, Giorgio , Raspagliesi, Francesco

Mayo Clinic

Journal of Gynecologic Oncology | August 20, 2018 | Volume: 29 | Issue: 6 | Pages: No page available

10.3802/jgo.2018.29.e94 | PMID 30207102 Get It

Distinguishing IgG4-Related Ophthalmic Disease From Graves Orbitopathy
Tooley, Andrea A. , Salomão, Diva R. , Garrity, James A., Bradley, Elizabeth A.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | August 19, 2018 | Volume: 35 | Issue: 2 | Pages: 170-176

10.1097/iop.0000000000001201 | PMID 30124607 Get It

Purpose: The authors aimed to determine key features of IgG4-related ophthalmic disease (IgG4-ROD) and Graves orbitopathy (GO) to aid in diagnosis. Methods: The authors retrospectively identified ophthalmology patients seen between June 2009 and November 2013 with clinical overlap of GO and IgG4-ROD. Patient findings were reviewed to characterize the 2 conditions. Results: Among 8 patients (7 male and 1 female), the mean age was 45.8 years. Time between diagnoses of GO and IgG4-ROD ranged from 1 month to 8 years. Imaging showed enlarged extraocular muscles in all patients. Enlarged infraorbital nerves were seen in 4 patients. Tissue biopsy showed CD20+ lymphocytes with a large proportion of IgG4 plasma cells in 7 of 8 orbital specimens. Six patients had a ratio of IgG4:IgG cells >40%. Discussion: No pathognomonic clinical findings for GO or IgG4-ROD have been reported, but some key features can help distinguish the conditions. GO is likely if findings include increased thyrotropin receptor antibodies, lid retraction/lid lag, and enlarged extraocular muscles with typical tendon-sparing morphology. Findings suggestive of IgG4-ROD include history of asthma and progressive orbital disease in patients with previous diagnosis of GO, disproportionately large lateral rectus muscle, and enlarged infraorbital nerves. Increased serum IgG4 level and biopsy showing >10 IgG4+ plasma cells/high-power field and IgG4:IgG ratio >40% will support the diagnosis of IgG4-ROD. Conclusions: GO and IgG4-ROD are complicated inflammatory processes affecting the orbit and present diagnostic challenges. The authors recommend biopsy for patients who do not follow the usual clinical course of GO or have clinical characteristics of IgG4-ROD.
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia
Abeykoon, Jithma P. , Zanwar, Saurabh , Ansell, Stephen M. , Gertz, Morie A. , King, Rebecca L. , Murray, David , Dingli, David , Muchtar, Eli , Inwards, David J. , Lacy, Martha Q. , Lin, Yi , Kourelis, Taxiarchis , Thompson, Carrie A. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Winters, Jeffrey, Gertz, Morie A , Go, Ronald S , Leung, Nelson , Buadi, Francis K. , Gonsalves, Wilson , Kourelis, Taxiarchis , Witzig, T.E. , Thompson, Carrie, Rajkumar, S Vincent , Muchtar, E , Dingli, David , Lin, Yi , Winters, Jeffrey L. , Habermann, Thomas M. , Go, Ronald S. , Leung, Nelson , Dispenzieri, Angela , Gonsalves, Wilson I. , Witzig, Thomas E. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | August 19, 2018 | Volume: 93 | Issue: 11 | Pages: 1384-1393

10.1002/ajh.25254 | PMID 30121949 Get It

AbstractSymptomatic hyperviscosity is a well‐established phenomenon in Waldenström macroglobulinemia (WM). Monoclonal IgM can variably impact intrinsic serum viscosity, leading to widely disparate symptomatic thresholds for development of hyperviscosity‐related symptoms. Data regarding the predictors of symptomatic hyperviscosity and outcomes related to this complication remain scarce and a recent study proposed that IgM >6000 mg/dL be considered a new criterion for initiating therapy in otherwise asymptomatic (smoldering) WM to pre‐empt hyperviscosity‐related injury. Herein, we attempt to identify predictors of the development of symptomatic hyperviscosity and its impact in patients with WM. Of 997 WM patients evaluated from January, 1996 through June, 2017, symptomatic hyperviscosity was observed in 130 (13%) patients. Overall survival (OS) of these 130 patients was similar to that of patients without symptomatic hyperviscosity (median: 11.5 vs 11.6 years; P = 0.63). On multivariate‐analysis, only viscosity >1.8 cp (risk ratio: 4.0, P = 0.02) assessed at the time of WM diagnosis was an independent predictor for the development of subsequent symptomatic hyperviscosity. Among patients with smoldering WM and IgM >6000 mg/dL at diagnosis (n = 13) who were managed expectantly, the median time‐to‐initial therapy was 6.9 years and only 15% developed hyperviscosity‐related symptoms subsequently. In summary, the occurrence of symptomatic hyperviscosity does not impact OS. Serum viscosity at diagnosis of WM, and not IgM concentration, represents the single most important independent predictor for development of subsequent hyperviscosity‐related symptoms. Patients with smoldering WM and high serum IgM can be safely observed in the absence of any indications per the Consensus recommendations to initiate WM‐directed therapy.
Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients
Laub, Melissa R. , Crow, Stacy A., Personett, Heather A. , Dierkhising, Ross , Boilson, Barry A. , Boilson, Barry, Razonable, Raymund, Razonable, Raymund R.

Mayo Clinic

Transplant Infectious Disease | August 18, 2018 | Volume: 20 | Issue: 6 | Pages: No page available

10.1111/tid.12979 | PMID 30120865 Get It

AbstractBackgroundTacrolimus is a cornerstone of immunosuppression after transplantation but is highly susceptible to changes from interacting variables and has a narrow therapeutic index. Clotrimazole troches are commonly used as a non‐systemic antifungal to prevent oral candidiasis. Studies suggest that clotrimazole troches, though minimally absorbed systemically, may affect tacrolimus concentrations by inhibition of metabolic enzyme activity in the intestines. However, the magnitude of the impact of clotrimazole on tacrolimus dosing requirements to maintain goal levels is not well described.MethodsTo assess this, tacrolimus dose adjustments and trough concentrations were retrospectively examined in 95 heart transplant recipients before and after the discontinuation of clotrimazole.ResultsThe median percent tacrolimus dose change was an increase of 66.7% (IQR28.6%, 100%) after clotrimazole discontinuation, and the median trough concentration percent change from baseline to the first trough after clotrimazole discontinuation (in the absence of a dose change) was −42.5% (IQR−52.3%, −30.9%). Five cases of allograft rejection were observed.ConclusionIn conclusion, clotrimazole troches exert a meaningful interaction with tacrolimus that requires close monitoring and dose adjustment. The data from this single‐center study provide novel information that could guide providers on the degree of tacrolimus dose adjustment needed when discontinuing clotrimazole prophylaxis after heart transplantation.
PERVading strategies and infectious risk for clinical xenotransplantation
McGregor, Christopher G.A. , Takeuchi, Yasu , Scobie, Linda , Byrne, Guerard W. , Byrne, Guerard

Mayo Clinic

Xenotransplantation | August 18, 2018 | Volume: 25 | Issue: 4 | Pages: No page available

10.1111/xen.12402 | PMID 30264876 Get It

Impact of Serum Cystatin C–Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients
Peters, Bradley J. , Mara, Kristin C. , Dierkhising, Ross , Frazee, Erin N. , Dierkhising, Ross A, Frazee, Erin N , Mara, Kristin C , Rule, Andrew D. , Kashani, Kianoush , Lieske, John C.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | August 18, 2018 | Volume: 38 | Issue: 10 | Pages: 1068-1073

10.1002/phar.2175 | PMID 30120844 Get It

Study Objective Serum creatinine ( S c r ) concentration is used to calculate estimated glomerular filtration rate (e GFR ) for medication dosing. Serum cystatin C (CysC) concentration has been proposed as an adjunct or alternative to S cr . This study sought to evaluate the possible impact of using CysC in eGFR equations on drug dose recommendations in hospitalized patients with infections. Design Retrospective analysis of prospectively collected data. Setting Large academic tertiary care medical center. Patients A total of 308 adults with suspected or documented infections and stable kidney function who were hospitalized between 2012 and 2015. Measurements and Main Results Standardized S c r and CysC measured at the time of antibiotic dosing were used to estimate GFR from the three Chronic Kidney Disease Epidemiology Collaborative ( CKD ‐ EPI ) equations using S c r (eGFR Cr ), CysC( eGFR CysC ), or a combination of S c r and CysC (eGFR Cr‐CysC ), and these values were compared with estimated creatinine clearance (eCl cr ) from the Cockcroft‐Gault equation (standard of care for drug dosage adjustments). The eGFR s were categorized into five common dosage adjustment strata (lower than 20, 20–49, 50–79, 80–130, and higher than 130 ml/min), and agreement between equations was tested with the weighted κ statistic. Recommended drug doses varied considerably between the eC l cr and the CKD ‐ EPI equations (weighted κ [95% confidence interval]: eGFR Cr 0.73 [0.68–0.79], eGFR CysC 0.42 [0.35–0.5], eGFR Cr‐CysC 0.65 [0.6–0.71]). If eGFR Cr, eGFR CysC , or eGFR Cr‐CysC were used instead of eC l cr to dose drugs, 11%, 12%, and 8% of doses, respectively, would be higher, and 12%, 38%, and 24% of doses, respectively, would be lower. Conclusion Significant discordance in drug doses was observed when the CKD ‐ EPI equations were used in place of eCl cr . When CysC was included in eGFR equations, recommended doses were often lower. Further study is needed to develop and test drug‐specific dosing guidelines that incorporate alternate renal biomarkers and/or more contemporary eGFR equations.
Management of low-grade glioma: a systematic review and meta-analysis
Bota, Daniela A. , Bent, Martin J. van den , Brown, Paul D. , Maher, Elizabeth A. , Aregawi, Dawit , Liau, Linda M. , Buckner, Jan C. , Weller, Michael , Glantz, Michael , Weller, Michael , van den Bent, Martin J , Brown, Timothy J. , Berger, Mitchel S.

Mayo Clinic

Neuro-Oncology Practice | August 18, 2018 | Volume: 6 | Issue: 4 | Pages: 249-258

10.1093/nop/npy034 | PMID 31386075 Get It

Abstract Background Optimum management of low-grade gliomas remains controversial, and widespread practice variation exists. This evidence-based meta-analysis evaluates the association of extent of resection, radiation, and chemotherapy with mortality and progression-free survival at 2, 5, and 10 years in patients with low-grade glioma. Methods A quantitative systematic review was performed. Inclusion criteria included controlled trials of newly diagnosed low-grade (World Health Organization Grades I and II) gliomas in adults. Eligible studies were identified, assigned a level of evidence for every endpoint considered, and analyzed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The relative risk of mortality and of progression at 2, 5, and 10 years was calculated for patients undergoing resection (gross total, subtotal, or biopsy), radiation, or chemotherapy. Results Gross total resection was significantly associated with decreased mortality and likelihood of progression at all time points compared to subtotal resection. Early radiation was not associated with decreased mortality; however, progression-free survival was better at 5 years compared to patients receiving delayed or no radiation. Chemotherapy was associated with decreased mortality at 5 and 10 years in the high-quality literature. Progression-free survival was better at 5 and 10 years compared to patients who did not receive chemotherapy. In patients with isocitrate dehydrogenase 1 gene (IDH1) R132H mutations receiving chemotherapy, progression-free survival was better at 2 and 5 years than in patients with IDH1 wild-type gliomas. Conclusions Results from this review, the first to quantify differences in outcome associated with surgery, radiation, and chemotherapy in patients with low-grade gliomas, can be used to inform evidence-based management and future clinical trials.
Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model
Akkad, Hazem, Cacciani, Nicola , Llano‐Diez, Monica , Kalamgi, Rebeca Corpeño, Kirkland, James L. , Larsson, Lars , Tchkonia, Tamara, Larsson, Lars , Tchkonia, Tamar

Mayo Clinic

Acta Physiologica | August 18, 2018 | Volume: 225 | Issue: 2 | Pages: No page available

10.1111/apha.13172 | PMID 30120816 Get It

Abstract Aim Critical illness myopathy ( CIM ) is a consequence of modern critical care, leading to skeletal muscle atrophy/paralysis with negative consequences for mortality/morbidity and health care costs. Glucocorticoids ( GC s) have been proposed to trigger CIM . Here, we compare outcomes of two GC s, the commonly used prednisolone and the newly developed dissociative vamorolone in response to the intensive care unit ( ICU ) condition for 5 days, ie, sedation, immobilization, and mechanical ventilation. Methods Rats were divided into a 0‐day sham‐operated control group, and three groups exposed to 5 days ICU condition during treatment with prednisolone ( PRED ) or vamorolone ( VAM ) or none of these GC s ( ICU ‐group). Survival, body and muscle weights, cytokine concentrations, regulation of muscle contraction in single fast‐ and slow‐twitch muscle fibres, myofibrillar protein expression and protein degradation pathways were studied. Results Critical illness myopathy geno‐ and pheno‐types were confirmed in the ICU group. However, VAM and PRED groups showed reduced atrophy/weakness than the ICU group, and muscle specific differences with more severe negative effects on fast‐twitch muscle fibres in the PRED than the other groups. Conclusion These results show that vamorolone provides a GC intervention superior to typical GC s in improving CIM outcomes. Further, the findings do not support the notion that moderate‐dose GC treatment represents a factor triggering CIM .